|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Alberta Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing AlbertaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
ResVerlogiX Corporation
| | | Phone: | (403) 254-9252 | Fax: | (403) 256-8495 | Year Established: | 2000 | Employees: | 32 | Ticker: | RVX | Exchange: | TSX | Main Contact: | Kenneth Lebioda, Senior VP Business & Corporate Development | | Other Contacts: | Ewelina Kulikowski, Ph.D., Senior VP, R&D Henrik C. Hansen, Ph.D., VP, IP A. Brad Cann, CA, CFO Michael Sweeney, M.D., Senior VP, Clinical Development Gregory S. Wagner, Ph.D., DABT, Senior VP Research & Development Jan O. Johansson, M.D., Ph.D., Senior VP, Medical Affairs Norman C.W. Wong, M.D., FRCP, CSO & Co-Founder Donald J. McCaffrey, President, CEO & Co-Founder
| | Company Description | ResVerlogiX is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. Resverlogix is developing RVX-208, a first-in-class small molecule for the treatment of atherosclerosis. RVX-208 is the first BET bromodomain inhibitor in clinical trials. New compounds arising from Resverlogix's epigenetic drug discovery platform function by inhibiting BET bromodomains and have the potential to impact multiple diseases including autoimmune diseases, cancer, neurodegenerative diseases and diabetes mellitus. | |
|
|
|
|
|